-transparent.png){kind=logo}
In recent years, somatostatin analogs have been proposed and used in the diagnosis and therapy in Cushing's syndrome (CS). In these last few years, the potential therapeutic effects of somatostain analogs have been studied in different aspects of CS. The strong expression of somatostatin receptors (SSTR) type 5 in human corticotroph cells and the demonstrated efficacy of SOM230, a novel multi-ligand somatostatin analog, in inhibiting ACTH release in vitro suggest that this new drug may be effective in the treatment of ACTH hypersecretion. Very preliminary in vivo results suggest that SOM230 could be a promising drug in medical therapy for patients with Cushing's disease (CD). Prolonged treatment and more data will be needed in order to evaluate its long-term therapeutic efficacy.
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
May 2017,
Endocrinologia, diabetes y nutricion,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
August 1996,
Metabolism: clinical and experimental,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
January 2004,
Pituitary,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
January 1983,
Annales chirurgiae et gynaecologiae,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
January 1994,
The Journal of clinical endocrinology and metabolism,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
January 1982,
Terapevticheskii arkhiv,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
August 1998,
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
February 1999,
Postgraduate medical journal,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
January 1994,
Digestion,
G Arnaldi, and
B Polenta, and
M Cardinaletti, and
M Boscaro
April 2009,
The New Zealand medical journal,
